SELECTIVE D-1 DOPAMINE RECEPTOR AGONIST TREATMENT OF PARKINSONS-DISEASE
SELECTIVE D-1 DOPAMINE RECEPTOR AGONIST TREATMENT OF PARKINSONS-DISEASE
复制标题
DOI：
10.1007/bf01244638
复制
发表时间：
1987-01-01
影响因子：
3.3
通讯作者：
CHASE, TN
中科院分区：
文献类型：
--
作者：
BRAUN, A;FABBRINI, G;CHASE, TN
临床前证据表明，D-1 多巴胺受体有助于产生用作人类锥体外系疾病模型的行为。为了评估 D-1 受体刺激在神经系统疾病中的潜力，在一项双盲、安慰剂对照研究中，对 7 名特发性帕金森病患者施用了 SKF 38393（一种选择性 D-1 多巴胺受体激动剂）。研究发现 SKF38393 口服后可迅速吸收，并在脊髓液中以微摩尔浓度存在。当单独使用 SKF38393 或与静脉注射左旋多巴联合使用时，帕金森病严重程度评分没有变化。结果支持这样的观点：帕金森病的病理生理学可能仅与多巴胺受体的 D-2 亚类相关。
Preclinical evidence suggests that the D-1 dopamine receptor contributes to the generation of behaviors used as models for human extrapyramidal disorders. To evaluate the potential of D-1 receptor stimulation in neurologic disease, SKF 38393, a selective D-1 dopamine receptor agonist, was administered to seven patients with idiopathic Parkinson''s disease in a double-blind, placebo controlled study. SKF38393 was found to be rapidly absorbed when administered orally, and to occur in micromolar concentrations in spinal fluid. No change in scores of parkinsonian severity were noted when SKF38393 was administered alone, or when the drug was combined with intravenous levodopa. The results support the view that the pathophysiology of Parkinson''s disease may relate exclusively to the D-2 subclass of dopamine receptors.